Anti-Müllerian hormone does not predict cumulative pregnancy rate in non-infertile women following four IUI cycles with donor sperm.

PURPOSE: To evaluate the predictive value of serum AMH for clinical pregnancy in non-infertile population undergoing intrauterine insemination with donor sperm (ds-IUI). METHODS: This multicenter prospective study (ClinicalTrials.gov ID: NCT06263192) recruited all non-infertile women undergoing ds-IUI from June 2020 to December 2022 in three different fertility clinics in Spain and Chile. Indications for ds-IUI included severe oligoasthenoteratozoospermia, female partner, or single status. Clinical pregnancy rates were compared between women with AMH ≥ 1.1 and < 1.1 ng/mL. The main outcome measure was the cumulative clinical pregnancy rate after up to 4 ds-IUI cycles. RESULTS: A total of 458 ds-IUI cycles were performed among 245 patients, of whom 108 (44.08%) achieved clinical pregnancy within 4 cycles, 60.2% of these occurring in the first attempt and 84.2% after two attempts. We found no significant differences in AMH levels or other parameters (such as age, BMI, FSH, AFC) between women who became pregnant and those who did not. Cumulative pregnancy rates and logistic regression analysis revealed that AMH ≥ 1.1 ng/mL was not predictive of ds-IUI success. While a high positive correlation was observed between AFC and AMH (r = 0.67, p < 0.001), ROC curve analyses indicated that neither of these ovarian reserve markers accurately forecasts cumulative ds-IUI outcomes in non-infertile women. CONCLUSIONS: The findings of this multicenter study suggest that AMH is not a reliable predictor of pregnancy in non-infertile women undergoing ds-IUI. Even women with low AMH levels can achieve successful pregnancy outcomes, supporting the notion that diminished ovarian reserve should not restrict access to ds-IUI treatments in eligible non-infertile women.

Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.

AIMS: Mosunetuzumab has received accelerated approval by the US Food and Drug Administration for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. We evaluated the cost-effectiveness of mosunetuzumab for the treatment of R/R FL from a US private payer perspective. MATERIALS AND METHODS: A partitioned survival model simulated lifetime costs and outcomes of mosunetuzumab against seven comparators: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), tazemetostat (taz, EZH2 wild-type only), rituximab plus lenalidomide (R-Len) or bendamustine (R-Benda), obinutuzumab plus bendamustine (O-Benda), and a retrospective real-world cohort (RW) based on current patterns of care derived from US electronic health records (Flatiron Health). Efficacy data for mosunetuzumab were from the pivotal Phase II GO29781 trial (NCT02500407). Relative treatment efficacy was estimated from indirect treatment comparisons (ITCs). Costs included were related to treatment, adverse events, routine care, and terminal care. Except for drug costs (March 2023), all costs were inflated to 2022 US dollars. Costs and quality-adjusted life-years (QALYs) were used to calculate incremental cost-effectiveness ratios (ICERs). Net monetary benefit (NMB) was calculated using a willingness-to-pay (WTP) threshold of $150,000/QALY. RESULTS: Mosunetuzumab dominated taz, tisa-cel, and axi-cel with greater QALYs and lower costs. Mosunetuzumab was projected to be cost-effective against R-Benda, O-Benda, and RW with ICERs of $78,607, $42,731, and $21,434, respectively. Mosunetuzumab incurred lower costs but lower QALYs vs. R-Len. NMBs showed that mosunetuzumab was cost-effective against comparators except R-Len. LIMITATIONS: Without head-to-head comparative data, the model had to rely on ITCs, some of which were affected by residual bias. Model inputs were obtained from multiple sources. Extensive sensitivity analyses assessed the importance of these uncertainties. CONCLUSION: Mosunetuzumab is estimated to be cost-effective compared with approved regimens except R-Len for the treatment of adults with R/R FL.

Evaluación multicéntrica del nuevo sistema analítico BioSystems BA 400 ® y comparación de procedimientos de medida / Multicentre evaluation of the new analytical system BioSystems BA 400 ® and comparison of measurement procedures

Objetivo. El objetivo de este trabajo fué evaluar, mediante un estudio multicéntrico, la imprecisión y la veracidad de un elevado número de procedimientos de medida en el nuevo sistema analítico BioSystems BA 400(R). Material y método. El estudio de la imprecisión se llevó a cabo siguiendo recomendaciones establecidas y utilizando sueros control con 2 concentraciones distintas. El estudio de la veracidad se ha realizado mediante la comparación de los procedimientos de medida del nuevo sistema con los utilizados habitualmente en los centros evaluadores. Resultados. Los resultados obtenidos para la imprecisión interdiaria con el nuevo analizador han sido en general excelentes en relación a los errores máximos permitidos. Se han encontrado algunas diferencias no despreciables y estadísticamente significativas entre los distintos procedimientos de medida, que son debidas a diferencias en el mensurando en algunos casos (transaminasas, inmunoanálisis) y a diferencias en los calibradores en otros. Conclusiones. La evaluación ha demostrado las excelentes prestaciones de precisión y veracidad del sistema. El nuevo analizador proporciona resultados en muestras de pacientes que son equivalentes a los obtenidos con otros analizadores (Olympus AU5400 y AU2700, Roche Cobas C711 y Siemens ADVIA 2400, 1800 y BNII) (AU)

Background. The purpose of the study was a multicentre evaluation of the imprecision and of the trueness of a wide variety of measurement procedures with the new analytical system BioSystems BA 400(R). Methods. The imprecision study was performed following established recommendations and using control sera with two different concentrations. The trueness was studied by means of a comparison of the measurement procedures of the new analyser with those of routine use in the evaluating centres. Results. The results obtained for the between-day imprecision with the new analyser have been in general excellent in relation to the maximum allowed errors. Several differences that are not worthless and that are statistically significant have been found between the measurement procedures. The differences are due to measurand differences in some cases (transaminases, immunoanalysis), and to the calibration in other. Conclusion. The evaluation study has demonstrated the excellent performance of the system regarding precision and trueness. The results obtained for patient samples with the new analyzer are equivalent to those obtained with other analyzers (Olympus AU5400 y AU2700, Roche Cobas C711 y Siemens ADVIA 2400, 1800 y BNII) (AU)

Propuesta para mejorar la sensibilidad del algoritmo diagnóstico de evaluación de la función tiroidea / Proposal to improve the sensitivity of the diagnostic algorithm for thyroid function evaluation

La medida en suero de la concentración de tirotropina y tiroxina es la base para la evaluación bioquímica de la función tiroidea. Con frecuencia, el intervalo de referencia de la tirotropina sirve como cribado inicial para valorar la necesidad de añadir la medida de tiroxina. Este trabajo se ha realizado con el objetivo de mejorar la sensibilidad diagnóstica del cribado. Se seleccionaron todos los resultados de tirotropina y tiroxina solicitados de manera simultánea a pacientes de consultas externas: para la primera parte del estudio se usaron los del año 2008 (n=10.900) y para la segunda parte, los de pacientes del año 2009 sin seguimiento en el año previo (n=5.367). Se realizaron dos curvas ROC para delimitar el intervalo de decisión del algoritmo con una sensibilidad del 90% y se contabilizó el número de resultados falsos negativos obtenidos. Los intervalos de tirotropina obtenidos en el primer y segundo estudio fueron (2,11-3,50) mint.u./L y (2,04-3,41) mint.u/L respectivamente. En ambos estudios la sensibilidad aumentó aproximadamente de un 70% de media con el intervalo de referencia a un 90% con el intervalo del algoritmo. El número de falsos negativos se redujo de 75 a 30 en el primer caso, y de 37 a 13 en el segundo. La aplicación de un intervalo de tirotropina calculado para la evaluación de la función tiroidea, en pacientes ambulatorios con o sin seguimiento previo, supone un aumento en la sensibilidad diagnóstica, respecto al empleo del intervalo de referencia de tirotropina (AU)

The measurement of thyrotropin and thyroxine concentrations in serum is the basis of the biochemical evaluation of thyroid function. The reference interval of thyrotropin is frequently used as an initial screening to assess the need for thyroxine measurement. This study was carried out to obtain a different and more adjusted interval of thyrotropin, in order to improve the diagnostic sensitivity. All of the results of thyrotropin and thyroxine requested at the same time on outpatients were selected: for the first part of the study, those from year 2008 (n=10,900), and for the second part, those from 2009 with no follow-up in the previous year (n=5,367). Two ROC curves were used to define the algorithm decision interval with a sensitivity of 90% and the number of false negative results was calculated. The thyrotropin intervals obtained in the first and second studies were (2.11-3.50) mIU/L and (2.04-3.41) mIU/L, respectively. In both studies, the sensitivity increased approximately from an average of 70% to 90% of the confidence interval using the algorithm interval. The number of false negatives was reduced from 75 to 30 in the first case, and from 37 to 13 in the second case. The application of a calculated thyrotropin interval to assess thyroid function in outpatients with or without prior monitoring, leads to an increase of the diagnostic sensitivity with regard to the use of the thyrotropin reference interval (AU)